Assimakis Komninos

White & Case (Brussels)
Lawyer (Partner)

Dr Assimakis Komninos is a Partner at the Brussels office of White & Case. Between 2009 and 2011 he was a Commissioner and Member of the Board of the Hellenic Competition Commission (HCC). He has acted before the European Court of Justice in Syfait v. GlaxoSmithKline and Lélos v. GlaxoSmithKline (parallel trade of pharmaceuticals - abuse of dominance), and in GlaxoSmithKline Services v. Commission (parallel trade of pharmaceuticals - Article 101). He was also involved before the EU General Court in Microsoft v. Commission (compulsory licensing of interoperability information), GlaxoSmithKline Services v. Commission (parallel trade of pharmaceuticals - application of Article 101), Chalkor Metal Works v. Commission (copper plumbing tubes) and Public Power Corporation v. Commission (Greek lignites). Dr Komninos successfully represented Aegean Airlines as lead counsel in Aegean/Olympic II, which resulted in the European Commission clearing the deal two years after it had previously blocked it. He has also represented or advised clients in proceedings before the Albanian, Cypriot, French, Greek, Kosovo and Romanian competition authorities and Belgian, Bulgarian, Cypriot, French, Greek, Latvian and Spanish appellate courts, and has particular expertise in arbitration cases involving EU and national competition issues, and in private antitrust litigation cases in national courts. Dr Komninos is currently a visiting fellow of the Centre for Law and Governance in Europe at University College London (UCL), where he teaches EU competition law, and a senior associate fellow of the Institute for European Studies (IES) at the Vrije Universiteit Brussels (VUB).


Auteurs associés

General Court of the European Union (Luxembourg)
Institut d’économie Industrielle (IDEI)
European Commission (Brussels)
Garrigues (Brussels)
University of Strasbourg
University College London
RBB Economics (Brussels)


Assimakis Komninos
Assimakis Komninos 28 octobre 2016 New York
Assimakis Komninos & Jacquelyn Maclennan, White & Case
Assimakis Komninos 25 mars 2014 Washington DC


17384 Bulletin

James Killick, Assimakis Komninos, Aqeel Kadri The UK Court of Appeal upholds the Competition Appeal Tribunal’s quashing of the Competition Autority’s decision against pharmaceutical undertakings who had abused their dominant position by pricing their epilepsy drug unfairly (Pfizer / Flynn Pharma)


On 10 March 2020 the Court of Appeal upheld the Competition Appeal Tribunal’s (CAT) quashing of the Competition and Markets Authority’s (CMA) decision that Pfizer and Flynn Pharma (Flynn) had abused their dominant positions in the market by pricing their epilepsy drug unfairly. Among other (...)

James Killick, Assimakis Komninos, Strati Sakellariou-Witt, Axel P. Schulz The UK Competition Authority closes its investigation into an allegedly abusive discount scheme in the pharmaceutical sector (Remicade)


This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. The CMA Remicade decision : discount schemes and abuse of dominance – effects matter !* Summary On 14 March 2019, the UK Competition and Markets Authority (CMA) (...)

Assimakis Komninos, James Killick The EU Court of Justice dismisses the Commission’s appeal against the annulment of its decision to prohibit a merger in the parcel delivery market (UPS / TNT)


This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. EU Court confirms the need for transparency and full disclosure of economic analyses in EU merger cases (UPS/TNT)* On 16 January 2019, the Court of Justice of (...)

Assimakis Komninos, James Killick The UK Competition Appeal Tribunal announces its provisional judgment in an appeal against the Competition Authority’s infringement decision in an excessive price case (Pfizer / Flynn)


I. Introduction In the last couple of years, there has been a trend for antitrust watchdogs around the world to investigate excessive pricing, especially in the phar- maceutical sector. Last year, the European Commission opened its first investigation into excessive pricing in the (...)

Assimakis Komninos, Jacquelyn MacLennan, James Killick, Jan Jeram, Jérémie Jourdan, Strati Sakellariou-Witt The EU Court of Justice endorses an effects-based assessment of rebates (Intel)


This article has been nominated for the 2018 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. On 6 September 2017, the Court of Justice of the European Union ("CJEU" or "Court") essentially held in Intel that the European Commission ("Commission") cannot (...)

Assimakis Komninos, Ian Forrester, James Killick The EU Court of Justice holds that parent companies may be fined for repeated infringements even without being an addressee of the earlier decisions (Versalis)


On 5 March 2015, the European Court of Justice (CoJ) handed down its judgment in Versalis , concerning the increasing of fines for antitrust infringements where a company is found to be a repeat offender. The judgment raises important questions about the respect for the rights of defence in EU (...)

Assimakis Komninos, Ian Forrester, Jacquelyn MacLennan, Kai Struckmann, Mark D. Powell, Pontus Lindfelt The European Commission adopts a package on private damages actions in antitrust cases


This article has been nominated for the 2014 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. Summary On 11 June 2013, the European Commission (“Commission”) adopted a proposal for a directive on how citizens and companies can bring damages claims under EU (...)

Assimakis Komninos The EU Court of Justice rules that the Greek Competition Authority is not a “court or tribunal” in the meaning of Art. 234 EC and therefore can not apply for an ECJ preliminary ruling (Syfait / GlaxoSmithKline)


On 31 May 2005 the European Court of Justice (ECJ) delivered its judgment in Case C-53/03, Syfait and others v. GlaxoSmithKline AEVE and GlaxoSmithKline plc (“Syfait”), which raises the question of whether a dominant pharmaceutical undertaking is under a duty to supply unlimited quantities of (...)

32487 Revue

Agisilaos Karpetas, Assimakis Komninos, Frédéric Jenny, Knut Fournier, Michèle Carpagnano La réparation des dommages concurrentiels dans les systèmes juridiques étrangers (La réparation des dommages concurrentiels en France et en Europe : État des lieux et changements à venir, Paris, 13 mai 2014)


La première table-ronde de la conférence qui s’est tenue le 13 mai 2014 à Paris sur le thème de la réparation des dommages concurrentiels était dédiée aux dommages concurrentiels dans les systèmes juridiques étrangers. Michele CARPAGNANO Professeur, Université de Trente Codirecteur, Osservatorio (...)

Antonello Schettino, Assimakis Komninos, Christopher Brown, Ekaterina Rousseva, Gianluca Faella, Victoria Mertikopoulou Efficiency defences in abuse of dominance cases


L’existence et l’application de la soi-disant "exception d’efficience" de l’article 102 du TFUE ont fait l’objet de grandes discussions ces dernières années. Le document d’orientation de 2009 a donné un nouvel essor à la notion. Les articles réunis dans ce tendances donnent le point de vue de l’Union (...)

Assimakis Komninos, David Bosco, Frédéric Marty, Hans Zenger, Strati Sakellariou-Witt Le test de l’opérateur aussi efficace : Une nouvelle ère ?


La Commission européenne voit dans le « test de l’opérateur aussi efficace » un test général applicable aux stratégies tarifaires des entreprises dominantes. Les contributions à ce Tendances présentent ce test dans les différents domaines où l’on le rencontre. Le sujet a d’autant plus d’intérêt que la (...)

Assimakis Komninos, Florence Ninane, Francesco Rosati, Geoffrey D. Oliver, Hendrik Bourgeois, Ioannis Lianos, James Killick, Johanne Peyre, Niamh McCarthy, Philippe Choné The EU guidance on exclusionary abuses : A step forward or a missed opportunity ?


What does the Commission’s recent Communication on enforcement of Article 82 EC mean for companies ? Does it make enforcement more predictable ? Does the greater use of economic concepts reduce the risk that intense competition on the merits by the part of a dominant firm will be considered (...)

Assimakis Komninos, Jose Luis Buendia, Pascal Berghe, Patrick Rey, Robert Kovar, Thierry Dahan Importations parallèles : Comment concilier intérêt du consommateur et intégration du marché communautaire ?


Cette deuxième table-ronde du colloque "Quel avenir pour les restrictions verticales ?" (Paris, 23 mai 2008) est dédiée aux questions posées par les importations parallèles. Les récentes affaires en matère de produits pharmaceutiques ont souligné l’importance des enjeux et la difficulté de (...)

Assimakis Komninos The EU White Paper for damages actions : A first appraisal


The European Commission has published early April 2008 its White Paper on damages actions for antitrust violations. The White Paper makes a number of important specific proposals with the aim to facilitate civil antitrust claims for damages in Europe that will certainly create a lot of (...)

Assimakis Komninos, Ian Forrester Agenda de Lisbonne et droit de la concurrence


La Commission européenne tend de plus en plus à faire référence aux objectifs de l’Agenda de Lisbonne, et plus particulièrement à la compétitivité des entreprises européennes dans ses discours sur la politique communautaire de concurrence. L’Agenda de Lisbonne est présenté comme l’objectif prioritaire de (...)


Envoyer un message